Insights into minimal residual disease in cancer patients: Implications for anti-cancer therapies

European Journal of Cancer

Volumn 46, Issue 7, 2010, Pages 1189-1197

  Müller, Volkmar ^a   Alix Panabières, Catherine ^b   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

Blood; Bone marrow; Breast cancer; Disseminated tumor cells; Micrometastasis; Prognosis

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; EPITHELIAL CELL ADHESION MOLECULE; LAPATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CXCR4; TRASTUZUMAB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CIRCULATING TUMOR CELL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOMETRY; DISSEMINATED TUMOR CELL; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MICROSCOPY; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; EPITHELIAL CELLS; FEMALE; HUMANS; MESODERM; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 77950690962     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.038     Document Type: Article

References (95)

1. Alix-Panabieres C., Riethdorf S., and Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 14 16 (2008) 5013-5021
2. Pantel K., Alix-Panabieres C., and Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 6 6 (2009) 339-351
3. Bilkenroth U., Taubert H., Riemann D., Rebmann U., Heynemann H., and Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int J Cancer 92 4 (2001) 577-582
4. Flatmark K., Bjornland K., Johannessen H.O., et al. Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 8 2 (2002) 444-449
5. Naume B., Borgen E., Beiske K., et al. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 6 2 (1997) 103-114
6. Martin V.M., Siewert C., Scharl A., et al. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol 26 3 (1998) 252-264
7. Naume B., Borgen E., Nesland J.M., et al. Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer 78 5 (1998) 556-560
8. Racila E., Euhus D., Weiss A.J., et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 95 8 (1998) 4589-4594
9. Pinzani P., Salvadori B., Simi L., et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 37 6 (2006) 711-718
10. Wong N.S., Kahn H.J., Zhang L., et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 99 1 (2006) 63-69
11. Zheng S., Lin H., Liu J.Q., et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 1162 2 (2007) 154-161
12. Zach O., and Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 18 1 (2006) 48-56
13. Hayes D.F., Cristofanilli M., Budd G.T., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12 14 (2006) 4218-4224
14. Riethdorf S., Fritsche H., Müller V., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13 3 (2007) 920-928
15. Bidard F.C., Vincent-Salomon A., Sigal-Zafrani B., et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 19 3 (2008) 496-500
16. Pantel K., and Alix-Panabieres C. The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 4 2 (2007) 62-63
17. Alix-Panabieres C., Vendrell J.P., Slijper M., et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 11 3 (2009) R39
18. Alix-Panabières C., Vendrell J.-P., Pellé O., et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53 3 (2007) 537-539
19. Schwarzenbach H., Alix-Panabieres C., Muller I., et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15 3 (2009) 1032-1038
20. Alix-Panabieres C., Rebillard X., Brouillet J.P., et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 51 8 (2005) 1538-1541
21. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450 7173 (2007) 1235-1239
22. Vredenburgh J.J., Silva O., Tyer C., et al. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 5 1 (1996) 57-62
23. Helzer K.T., Barnes H.E., and Day L. Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model. Cancer Res 69 19 (2009) 7860-7866
24. Pachmann K., Clement J.H., Schneider C.P., et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 43 6 (2005) 617-627
25. Marrinucci D., Bethel K., Bruce R.H., et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 38 3 (2007) 514-519
26. Ntouroupi T.G., Ashraf S.Q., McGregor S.B., et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Brit J Cancer 99 5 (2008) 789-795
27. Deng G., Herrler M., Burgess D., Manna E., Krag D., and Burke J.F. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 10 4 (2008) R69
28. Datta Y.H., Adams P.T., Drobyski W.R., Ethier S.P., Terry V.H., and Roth M.S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12 3 (1994) 475-482
29. Schoenfeld A., Kruger K.H., Gomm J., et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 33 6 (1997) 854-861
30. Smith B.M., Slade M.J., English J., et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 18 7 (2000) 1432-1439
31. Berois N., Varangot M., Aizen B., et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer 36 6 (2000) 717-723
32. Benoy I.H., Elst H., Philips M., et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Brit J Cancer 94 5 (2006) 672-680
33. Lankiewicz S., Rivero B.G., and Bocher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol Biotechnol 34 1 (2006) 15-27
34. Fehm T., Hoffmann O., Aktas B., et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11 4 (2009) R59
35. Schmitt M., and Foekens J.A. Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells. Breast Cancer Res 11 5 (2009) 109
36. Berx G., Raspe E., Christofori G., Thiery J.P., and Sleeman J.P. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastas 24 8 (2007) 587-597
37. Mani S.A., Guo W., Liao M.J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 4 (2008) 704-715
38. Müller V., Stahmann N., Riethdorf S., et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11 10 (2005) 3678-3685
39. Pierga J.Y., Bonneton C., Vincent-Salomon A., et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10 4 (2004) 1392-1400
40. Sieuwerts A.M., Kraan J., Bolt J., et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101 1 (2009) 61-66
41. Gebauer G., Fehm T., Merkle E., Beck E.P., Lang N., and Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19 16 (2001) 3669-3674
42. Gerber B., Krause A., Muller H., et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19 4 (2001) 960-971
43. Braun S., Pantel K., Muller P., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. New Engl J Med 342 8 (2000) 525-533
44. Wiedswang G., Borgen E., Karesen R., et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21 18 (2003) 3469-3478
45. Cote R.J., Rosen P.P., Lesser M.L., Old L.J., and Osborne M.P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9 10 (1991) 1749-1756
46. Diel I.J., Kaufmann M., Costa S.D., et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88 22 (1996) 1652-1658
47. Mansi J.L., Gogas H., Bliss J.M., Gazet J.C., Berger U., and Coombes R.C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354 9174 (1999) 197-202
48. Braun S., Vogl F.D., Naume B., et al. International pooled analysis of prognostic significance of bone marrow micrometastasis in patients with stage I, II, or III breast cancer. New Engl J Med 353 8 (2005) 793-802
49. Witzig T.E., Bossy B., Kimlinger T., et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 8 5 (2002) 1085-1091
50. Kraeft S.K., Sutherland R., Gravelin L., et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res 6 2 (2000) 434-442
51. Pachmann K., Camara O., Kavallaris A., et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 26 8 (2008) 1208-1215
52. Ntoulia M., Stathopoulou A., Ignatiadis M., et al. Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 39 9 (2006) 879-887
53. Xenidis N., Perraki M., Kafousi M., et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24 23 (2006) 3756-3762
54. Quintela-Fandino M., Lopez J.M., Hitt R., et al. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol 24 22 (2006) 3611-3618
55. Cristofanilli M., and Mendelsohn J. Circulating tumor cells in breast cancer: advanced tools for "tailored" therapy?. Proc Natl Acad Sci USA 103 46 (2006) 17073-17074
56. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med 351 8 (2004) 781-791
57. Budd G.T., Cristofanilli M., Ellis M.J., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12 21 (2006) 6403-6409
58. De Giorgi U., Valero V., Rohren E., et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27 20 (2009) 3303-3311
59. [accessed 10.11.09].
60. Janni W., Rack B., Schindlbeck C., et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103 5 (2005) 884-891
61. Braun S., Kentenich C., Janni W., et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18 1 (2000) 80-86
62. Wiedswang G., Borgen E., Karesen R., et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10 16 (2004) 5342-5348
63. Janni W., Wiedswang G., Fehm T., et al. Persistence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients predicts increased risk for relapse - results of pooled European data. J Clin Oncol 24 18S (2006) Abstract 10083
64. Rack B., Schindlbeck C., Hofmann S., et al. Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients. J Clin Oncol 25 18S (2007) Abstract 10595
65. Pantel K., Brakenhoff R.H., and Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8 5 (2008) 329-340
66. Stoecklein N.H., Hosch S.B., Bezler M., et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13 5 (2008) 441-453
67. Shah S.P., Morin R.D., Khattra J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461 7265 (2009) 809-813
68. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3 6 (2003) 453-458
69. Klein C.A. Parallel progression of primary tumours and metastases. Nat Rev Cancer 9 4 (2009) 302-312
70. Pierga J.Y., Bidard F.C., Mathiot C., et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14 21 (2008) 7004-7010
71. Bartkowiak K., Wieczorek M., Buck F., et al. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res 8 4 (2009) 2004-2014
72. Trumpp A., and Wiestler O.D. Mechanisms of disease: cancer stem cells - targeting the evil twin. Nat Clin Pract Oncol 5 6 (2008) 337-347
73. Santini D., Vespasiani Gentilucci U., Vincenzi B., et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14 10 (2003) 1468-1476
74. Aft R., Watson M., Ylagan L., et al. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2008) 26 Abstract 1021
75. Rack B., Janni W., Schoberth A., et al. Secondary adjuvant therapy with zoledronate in patients with early breast cancer: is there an effect on persisting isolated tumor cells (ITC) in the bone marrow (BM)?. Breast Cancer Res Treat 88 Suppl. 1 (2004) Abstract 6019
76. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New Engl J Med 339 6 (1998) 357-363
77. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 360 7 (2009) 679-691
78. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353 16 (2005) 1673-1684
79. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 353 16 (2005) 1659-1672
80. Solomayer E.F., Becker S., Pergola-Becker G., et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 98 2 (2006) 179-184
81. Wülfing P., Borchard J., Buerger H., et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12 6 (2006) 1715-1720
82. Meng S., Tripathy D., Shete S., et al. UPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103 46 (2006) 17361-17365
83. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101 25 (2004) 9393-9398
84. Braun S., Schlimok G., Heumos I., et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61 (2001) 1890-1895
85. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 357 26 (2007) 2666-2676
86. Kallergi G., Markomanolaki H., Giannoukaraki V., et al. Hypoxia inducible factor 1 alpha and vascular endothelial growth factor expression in CTCs of breast cancer patients. Breast Cancer Res 11 6 (2009) R84
87. Shackleton M., Vaillant F., Simpson K.J., et al. Generation of a functional mammary gland from a single stem cell. Nature 439 7072 (2006) 84-88
88. Clarke M.F., and Fuller M. Stem cells and cancer: two faces of eve. Cell 124 6 (2006) 1111-1115
89. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. New Engl J Med 356 3 (2007) 217-226
90. Becker S., Becker-Pergola G., Wallwiener D., Solomayer E.F., and Fehm T. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat 97 1 (2006) 91-96
91. Becker S., Solomayer E., Becker-Pergola G., Wallwiener D., and Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 106 2 (2007) 239-243
92. Balic M., Lin H., Young L., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12 19 (2006) 5615-5621
93. Wicha M.S. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 12 19 (2006) 5606-5607
94. Galie M., Konstantinidou G., Peroni D., et al. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene 27 18 (2008) 2542-2551
95. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol (2009) 10.1097/COC.0b013e318191bfb0